Cargando…
Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective
Efforts to reduce non-urgent hospital attendances during the COVID-19 pandemic have been the focus of much attention from healthcare professionals worldwide. In Ireland, due to funding constraints omalizumab is only available for hospital-based administration. Fifty-eight patients with chronic spont...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
World Allergy Organization
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452509/ https://www.ncbi.nlm.nih.gov/pubmed/34567347 http://dx.doi.org/10.1016/j.waojou.2021.100587 |
_version_ | 1784570085035212800 |
---|---|
author | King, Catherine Cox, Fionnuala Sloan, Anne McCrea, Patricia Edgar, J.David Conlon, Niall |
author_facet | King, Catherine Cox, Fionnuala Sloan, Anne McCrea, Patricia Edgar, J.David Conlon, Niall |
author_sort | King, Catherine |
collection | PubMed |
description | Efforts to reduce non-urgent hospital attendances during the COVID-19 pandemic have been the focus of much attention from healthcare professionals worldwide. In Ireland, due to funding constraints omalizumab is only available for hospital-based administration. Fifty-eight patients with chronic spontaneous urticaria and angioedema (CSU) receiving omalizumab in our centre were rapidly transitioned to home self-administration at the start of the pandemic. We conducted an anonymised patient survey after 3 months of home therapy with the aim of characterizing the patient experience throughout this period. 41 patients participated in our questionnaire (71% response rate). 93% of patients favored self-injection of omalizumab from home, with respondents citing cost savings, time savings, improved flexibility, fewer hospital visits, and less risk of exposure to COVID-19 infection as particular benefits. Concerns regarding home administration including injecting incorrectly, forgetting a dose, or having a reaction were reported very infrequently. Eighty-three percent (83%) of patients wished to continue with home therapy long-term. This survey highlights broadly positive experiences for patients rapidly transitioning to home omalizumab administration. This data will be useful to inform healthcare funders in decisions regarding patient-centred care in CSU. Facilitating home omalizumab therapy in suitable CSU patients should be strongly considered in the post-pandemic setting. |
format | Online Article Text |
id | pubmed-8452509 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | World Allergy Organization |
record_format | MEDLINE/PubMed |
spelling | pubmed-84525092021-09-21 Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective King, Catherine Cox, Fionnuala Sloan, Anne McCrea, Patricia Edgar, J.David Conlon, Niall World Allergy Organ J Article Efforts to reduce non-urgent hospital attendances during the COVID-19 pandemic have been the focus of much attention from healthcare professionals worldwide. In Ireland, due to funding constraints omalizumab is only available for hospital-based administration. Fifty-eight patients with chronic spontaneous urticaria and angioedema (CSU) receiving omalizumab in our centre were rapidly transitioned to home self-administration at the start of the pandemic. We conducted an anonymised patient survey after 3 months of home therapy with the aim of characterizing the patient experience throughout this period. 41 patients participated in our questionnaire (71% response rate). 93% of patients favored self-injection of omalizumab from home, with respondents citing cost savings, time savings, improved flexibility, fewer hospital visits, and less risk of exposure to COVID-19 infection as particular benefits. Concerns regarding home administration including injecting incorrectly, forgetting a dose, or having a reaction were reported very infrequently. Eighty-three percent (83%) of patients wished to continue with home therapy long-term. This survey highlights broadly positive experiences for patients rapidly transitioning to home omalizumab administration. This data will be useful to inform healthcare funders in decisions regarding patient-centred care in CSU. Facilitating home omalizumab therapy in suitable CSU patients should be strongly considered in the post-pandemic setting. World Allergy Organization 2021-09-21 /pmc/articles/PMC8452509/ /pubmed/34567347 http://dx.doi.org/10.1016/j.waojou.2021.100587 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article King, Catherine Cox, Fionnuala Sloan, Anne McCrea, Patricia Edgar, J.David Conlon, Niall Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective |
title | Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective |
title_full | Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective |
title_fullStr | Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective |
title_full_unstemmed | Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective |
title_short | Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective |
title_sort | rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the covid-19 pandemic: a patient perspective |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452509/ https://www.ncbi.nlm.nih.gov/pubmed/34567347 http://dx.doi.org/10.1016/j.waojou.2021.100587 |
work_keys_str_mv | AT kingcatherine rapidtransitiontohomeomalizumabtreatmentforchronicspontaneousurticariaduringthecovid19pandemicapatientperspective AT coxfionnuala rapidtransitiontohomeomalizumabtreatmentforchronicspontaneousurticariaduringthecovid19pandemicapatientperspective AT sloananne rapidtransitiontohomeomalizumabtreatmentforchronicspontaneousurticariaduringthecovid19pandemicapatientperspective AT mccreapatricia rapidtransitiontohomeomalizumabtreatmentforchronicspontaneousurticariaduringthecovid19pandemicapatientperspective AT edgarjdavid rapidtransitiontohomeomalizumabtreatmentforchronicspontaneousurticariaduringthecovid19pandemicapatientperspective AT conlonniall rapidtransitiontohomeomalizumabtreatmentforchronicspontaneousurticariaduringthecovid19pandemicapatientperspective |